GLOBAL PROJECT DELIVERY

MENA · Africa · Central Asia · Europe · Americas

Direct investor desk ↗
Home/ Projects/ Molecular Test Production
Diagnostics manufacturing · INVESTOR TECHNICAL BRIEF

Molecular Test Production

PCR and RT-qPCR reagent and kit production from oligonucleotide control through validated finished kits.

Request feasibility study ↗
Indicative CAPEX
USD 2.4–6.8M
Delivery period
12–18 months from approved design basis to validated pilot batch
Installed capacity
Tier 1: 1–3M tests/year
Regulatory endpoint
ISO 13485 QMS readiness; IVDR technical-documentation and local registration pathway
01

What the facility produces and why it matters locally

PCR and RT-qPCR reagent and kit production from oligonucleotide control through validated finished kits. The investment case is tested against import dependency, procurement demand, supply resilience, attainable local content and regional export access. Portfolio definition precedes equipment selection so capital is not locked into an incompatible process.

02

Indicative capital band

USD 2.4–6.8M. The range covers core equipment, controlled environments, process utilities, installation, qualification, technology transfer and initial training at the stated tier. Preliminary engineering range; excludes land, finance cost, taxes and import duty. Final scope and price are confirmed at the feasibility gate.

03

Footprint and clean environment

1,200–2,800 m² gross; 350–900 m² controlled production, typically ISO 8 with ISO 7 formulation/filling zones where risk assessment requires.

ISO 8 background is typical for reagent preparation support; ISO 7 local zones may be specified for exposed formulation/filling. Pre- and post-amplification QC rooms are physically separated to control amplicon contamination.

04

Programme from design basis to operation

01 Feasibility & design basis02 Architecture & process engineering03 Infrastructure & clean environment04 Equipment procurement and FAT05 Installation, SAT and qualification06 Process validation and training07 Operational handover

12–18 months from approved design basis to validated pilot batch. Permit, authority review, civil-condition, customs and client approval delays sit outside the base programme unless expressly contracted.

05

Installed capacity tiers

Tier 1: 1–3M tests/year; Tier 2: 5–12M tests/year; two shifts, product mix and lyophilisation cycle dependent.

Capacity assumes qualified materials, stated shifts, planned maintenance and validated yield; it is not the sum of nominal machine speeds.

06

Process flow and utilities

Core process

  • Controlled receipt and segregation of primers, probes, enzymes and master-mix inputs
  • Primer/probe dilution and identity control
  • Master-mix formulation under temperature control
  • Aliquoting or lyophilisation where selected
  • Component kitting, labelling and controlled cold storage
  • Analytical performance, stability and batch-release programme

Site and utilities

Redundant power, 18–25°C temperature control, humidity control where lyophilised formats are handled, monitored 2–8°C and frozen storage, purified water where formulation requires, segregated QC airflow and data backup.

07

Regulatory and quality endpoint

ISO 13485 QMS readiness; IVDR technical-documentation and local registration pathway. Typical facility/QMS readiness: 9–15 months; product registration is authority-dependent.

Infinity IVD delivers the contracted facility, QMS, validation and dossier work. Certification or market authorisation is granted only by the competent independent authority.

08

Staffing and transfer of know-how

Indicative 22–55 FTE across production, molecular QC, QA, regulatory, warehouse, maintenance and supervision; 6–12 weeks role-based training plus supervised pilot batches.

09

Equipment classes and procurement boundary

  • Calibrated liquid handling and cold-chain systems
  • PCR/RT-qPCR QC platforms and extraction systems
  • Automated or semi-automated filling, capping and labelling
  • Lyophiliser and moisture-control equipment when freeze-dried format is selected
  • Environmental monitoring and temperature mapping

The feasibility equipment register identifies supplied equipment, client-supplied items, spares, initial consumables, FAT/SAT responsibility, calibration and qualification ownership.

10

Critical process risks and operating economics

  • Primer/probe mix-up or degradation
  • Enzyme activity loss through temperature excursion
  • Cross-contamination and false-positive QC signals
  • Fill-volume drift
  • Stability failure across transport conditions

Operating economics are issued as a sensitivity model using local labour, utilities, materials, yield, utilisation and financing assumptions; they are not a guaranteed return.

11

Relevant delivery evidence

  • Türkiye — molecular diagnostics production portfolio
  • Germany — PCR production technology programme, client confidential
  • United States — PCR localisation programme, client confidential

Client names and photography are disclosed only with permission; confidential programmes retain a technical envelope rather than an invented attribution.

Review programme evidence ↗
Project desk